A Double-Blinded Phase II Study of the Expression of Ki-67/MIB-1 in Women With Hyperplasia of the Breast Randomized to Receive Daily Celecoxib 400 mg BID [twice per day] or Placebo.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Celecoxib (Primary)
- Indications Breast cancer; Hyperplasia
- Focus Therapeutic Use
- 06 Nov 2016 Biomarkers information updated
- 23 Feb 2011 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
- 23 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.